A new medication known as Rexulti has been approved by the U.S. Food and Drug Administration (FDA) and released onto the market in 2015. Rexulti is an antipsychotic, used to treat a variety of disorders including schizophrenia and major depression.
Rexulti was developed to be a newer drug similar to the antipsychotic Abilify, which according to an Abilify FDA warning letter has been associated with significant side effects, including compulsive behaviors like gambling, shopping, and sexual addiction. Because Rexulti is essentially Abilify’s successor, with a very similar profile, it is possible that the side effects will be similar for patients taking Rexulti.
Abilify (also known by its generic name, aripiprazole) is a popular antipsychotic medication manufactured jointly by Otsuka Pharmaceuticals and Bristol-Myers Squibb and approved by the FDA back in 2002. Used to treat schizophrenia and depression, Abilify has increased in popularity and now brings in billions of dollars annually.
However, Abilify has also been linked in post-marketing reports with compulsive gambling, shopping, and sexual addictions, whether or not patients had a prior history with these problems.
The newer drug Rexulti, approved just in 2015, may have similar complications for patients because of its other similarities with Abilify. Both antipsychotics are part of a class of drugs known as dopamine D2 receptor partial agonists, and both function by activating or blocking specific serotonin receptors, making their profiles very similar. One key difference is that Rexulti is an even…